Hypercholesterolemia | HR (95% CI) | P Value | No hypercholesterolemia | HR (95% CI) | P Value | P for interaction |
---|---|---|---|---|---|---|
Model 1 | Â | Â | Model 1 | Â | Â | 0.867 |
 Quartile 1: MHR < 0.33 | Reference |  | Quartile 1: MHR < 0.33 | Reference |  |  |
 Quartile 2: 0.33 ≤ MHR < 0.46 | 1.45 (1.00–2.09) | 0.051 | Quartile 2: 0.33 ≤ MHR < 0.46 | 2.46 (1.28–4.71) | 0.007 |  |
 Quartile 3: 0.46 ≤ MHR < 0.62 | 1.73 (1.20–2.47) | 0.003 | Quartile 3: 0.46 ≤ MHR < 0.62 | 3.11 (1.65–5.86) |  < 0.001 |  |
 Quartile 4: MHR ≥ 0.62 | 2.66 (1.90–3.72) |  < 0.001 | Quartile 4: MHR ≥ 0.62 | 3.19 (1.66–6.11) |  < 0.001 |  |
 Continuous | 1.37 (0.67–2.82) | 0.389 | Continuous | 2.94 (1.51–5.73) | 0.001 |  |
Model 2 | Â | Â | Model 2 | Â | Â | 0.963 |
 Quartile 1: MHR < 0.33 | Reference |  | Quartile 1: MHR < 0.33 | Reference |  |  |
 Quartile 2: 0.33 ≤ MHR < 0.46 | 1.48 (1.02–2.16) | 0.041 | Quartile 2: 0.33 ≤ MHR < 0.46 | 2.23 (1.15–4.31) | 0.017 |  |
 Quartile 3: 0.46 ≤ MHR < 0.62 | 1.78 (1.24–2.57) | 0.002 | Quartile 3: 0.46 ≤ MHR < 0.62 | 2.82 (1.45–5.46) | 0.002 |  |
 Quartile 4: MHR ≥ 0.62 | 2.74 (1.94–3.89) |  < 0.001 | Quartile 4: MHR ≥ 0.62 | 2.93 (1.52–5.65) | 0.001 |  |
 Continuous | 1.33 (0.65–2.72) | 0.431 | Continuous | 2.55 (1.30–5.02) | 0.007 |  |
Model 3 | Â | Â | Model 3 | Â | Â | 0.803 |
 Quartile 1: MHR < 0.33 | Reference |  | Quartile 1: MHR < 0.33 | Reference |  |  |
 Quartile 2: 0.33 ≤ MHR < 0.46 | 1.46 (0.99–2.14) | 0.053 | Quartile 2: 0.33 ≤ MHR < 0.46 | 2.26 (1.09–4.69) | 0.029 |  |
 Quartile 3: 0.46 ≤ MHR < 0.62 | 1.61 (1.11–2.33) | 0.011 | Quartile 3: 0.46 ≤ MHR < 0.62 | 3.38 (1.62–7.09) | 0.001 |  |
 Quartile 4: MHR ≥ 0.62 | 2.17 (1.50–3.13) |  < 0.001 | Quartile 4: MHR ≥ 0.62 | 3.29 (1.49–7.27) | 0.003 |  |
 Continuous | 1.17 (0.55–2.50) | 0.687 | Continuous | 1.86 (0.79–4.35) | 0.153 |  |